{"success":true,"data":{"pressRelease":{"id":"52868","rtpr_id":"nGNX2Rx2f4","ticker":"FATE","exchange":"NASDAQ","all_tickers":["FATE"],"title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-06-02T20:05:00.197Z","article_body":"SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:\nFATE), a clinical-stage biopharmaceutical company dedicated to bringing a\ntransformative pipeline of induced pluripotent stem cell (iPSC)-derived\ncellular immunotherapies broadly to patients with cancer and autoimmune\ndiseases, today announced that on June 1, 2026, the Company granted restricted\nstock units (RSUs) representing 67,300 shares of its common stock to two\nnewly-hired non-executive employees. The grants were approved by the\nCompensation Committee of the Company’s Board of Directors and granted under\nthe Company’s Amended and Restated Inducement Equity Plan as an inducement\nmaterial to the new employees entering into employment with the Company in\naccordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four\nyears, with 25% of the shares underlying each RSU award vesting on each\nanniversary of the grant date, subject to the employees being continuously\nemployed by the Company through each vesting date.\n\nAbout Fate Therapeutics, Inc.\nFate Therapeutics is a clinical-stage biopharmaceutical company dedicated to\nbringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular\nimmunotherapies to patients. Using its proprietary iPSC product platform, the\nCompany has established a leadership position in creating\nmultiplexed-engineered master iPSC lines and in the manufacture and clinical\ndevelopment of off-the-shelf, iPSC-derived cell products. The Company’s\npipeline includes iPSC-derived T-cell and natural killer (NK) cell product\ncandidates, which are selectively designed, incorporate novel synthetic\ncontrols of cell function, and are intended to deliver multiple therapeutic\nmechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA.\nFor more information, please visit www.fatetherapeutics.com.\n\nContact:\nRyan Douglas\nFate Therapeutics, Inc.\nIR@fatetherapeutics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2Rx2f4","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"FATE","created":"2026-06-02T20:05:00.197Z","tickers":["FATE"],"exchange":"NASDAQ","article_body":"SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:\nFATE), a clinical-stage biopharmaceutical company dedicated to bringing a\ntransformative pipeline of induced pluripotent stem cell (iPSC)-derived\ncellular immunotherapies broadly to patients with cancer and autoimmune\ndiseases, today announced that on June 1, 2026, the Company granted restricted\nstock units (RSUs) representing 67,300 shares of its common stock to two\nnewly-hired non-executive employees. The grants were approved by the\nCompensation Committee of the Company’s Board of Directors and granted under\nthe Company’s Amended and Restated Inducement Equity Plan as an inducement\nmaterial to the new employees entering into employment with the Company in\naccordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four\nyears, with 25% of the shares underlying each RSU award vesting on each\nanniversary of the grant date, subject to the employees being continuously\nemployed by the Company through each vesting date.\n\nAbout Fate Therapeutics, Inc.\nFate Therapeutics is a clinical-stage biopharmaceutical company dedicated to\nbringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular\nimmunotherapies to patients. Using its proprietary iPSC product platform, the\nCompany has established a leadership position in creating\nmultiplexed-engineered master iPSC lines and in the manufacture and clinical\ndevelopment of off-the-shelf, iPSC-derived cell products. The Company’s\npipeline includes iPSC-derived T-cell and natural killer (NK) cell product\ncandidates, which are selectively designed, incorporate novel synthetic\ncontrols of cell function, and are intended to deliver multiple therapeutic\nmechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA.\nFor more information, please visit www.fatetherapeutics.com.\n\nContact:\nRyan Douglas\nFate Therapeutics, Inc.\nIR@fatetherapeutics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-02T20:05:00.228986388Z","server_sent_at_ms":1780430700228},"received_at":"2026-06-02T20:05:00.377Z","source_url":null},"analysis":{"id":"42296","press_release_id":"52868","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"insider_transaction","narrative":"Fate Therapeutics granted 67,300 restricted stock units to two newly hired non-executive employees.\n\nThe awards were approved by the Compensation Committee as inducements material to the new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe RSUs vest over four years, with 25% vesting annually, subject to continued employment.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine employee inducement disclosure; no material strategic impact."},"keyFigures":{"customDimensions":{"rsu_shares_granted":67300,"vesting_period_years":4}},"quotedText":"The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).","namedEntities":{"people":[{"name":"Ryan Douglas","role":"IR Contact"}],"products":[],"companies":[{"name":"Fate Therapeutics, Inc.","ticker":"FATE"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine disclosure of employee inducement awards (67,300 RSUs) for two non-executive hires. This is a standard compliance filing under Nasdaq Rule 5635(c)(4) with negligible dilution and no strategic signal."},"tickerRelevance":{"others":[],"primary":"FATE"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_compliance","dilutionImpact":"negligible","strategicSignal":"none"}},"event_type":"insider_transaction","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Fate Therapeutics granted 67,300 restricted stock units to two newly hired non-executive employees.\n\nThe awards were approved by the Compensation Committee as inducements material to the new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).\n\nThe RSUs vest over four years, with 25% vesting annually, subject to continued employment.","key_figures":{"customDimensions":{"rsu_shares_granted":67300,"vesting_period_years":4}},"named_entities":{"people":[{"name":"Ryan Douglas","role":"IR Contact"}],"products":[],"companies":[{"name":"Fate Therapeutics, Inc.","ticker":"FATE"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T20:05:40.439Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_compliance","dilutionImpact":"negligible","strategicSignal":"none"}},"durationMs":40037,"modelName":"george-droid-qwen-72b"}}